Physician profile
James S Abraham
NPI 1205882057
$546.40
in general payments reported to CMS, 2019-2025
18 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.64 · 2021: $28.74 · 2022: $46.68 · 2024: $89.29 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $72.58 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $64.87 | 2022-2025 | |
| Amgen INC. | $51.45 | 2025 | Repatha |
| Scpharmaceuticals INC. | $45.57 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $39.78 | 2024-2025 | Uptravi, Opsumit |
| Heartflow, INC. | $37.57 | 2025 | |
| Edwards Lifesciences Corporation | $27.55 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Cvrx, INC. | $26.35 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $25.56 | 2025 | Camzyos |
| Novo Nordisk INC | $20.32 | 2024 | Ozempic |
| Ionis Pharmaceuticals, INC. | $19.86 | 2025 | Tryngolza |
| Astrazeneca Pharmaceuticals LP | $19.85 | 2025 | Farxiga |
| Irhythm Technologies, INC. | $19.84 | 2024 | Zio Monitor, Zio Xt Patch |
| Pfizer INC. | $17.67 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.20 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.40 | 2021 | |
| Abbott Laboratories | $14.34 | 2021 | |
| Lantheus Medical Imaging, INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.